Free tool
Oncology stocks
We cover 39 companies grouped under the Oncology theme. The median market value in the group is $84.35M. Across the group, the median move over the past trading day is −0.24%. 47% of the 38 with a 200-day average trade above it. Price change over the past year runs from −77.1% to +365.6% across the middle 80 percent of the group, with a median of −7.8%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
39 of 319 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return | Next report |
|---|---|---|---|---|---|
| 4528.T | Ono Pharmaceutical Co., Ltd. | $7.39B | Mid cap | +54.43% | Oct 29, 2026 |
| CGON | CG Oncology, Inc. | $6.95B | Mid cap | +196.15% | Nov 9, 2026 |
| ERAS | Erasca, Inc. | $6.70B | Mid cap | +1112.03% | Nov 11, 2026 |
| LNTH | Lantheus Holdings, Inc. | $6.58B | Mid cap | +77.38% | Nov 5, 2026 |
| COGT | Cogent Biosciences, Inc. | $6.39B | Mid cap | +196.85% | Nov 3, 2026 |
| CELC | Celcuity Inc. | $4.65B | Mid cap | +90.31% | Nov 11, 2026 |
| ELVN | Enliven Therapeutics, Inc. | $4.46B | Mid cap | +194.32% | Nov 11, 2026 |
| TNGX | Tango Therapeutics, Inc. | $4.29B | Mid cap | +269.13% | Nov 4, 2026 |
| RLAY | Relay Therapeutics, Inc. | $4.26B | Mid cap | +445.10% | Nov 5, 2026 |
| RCUS | Arcus Biosciences, Inc. | $3.92B | Mid cap | +191.29% | Oct 27, 2026 |
| IMNM | Immunome, Inc. | $3.34B | Mid cap | +188.94% | Nov 5, 2026 |
| SLS | SELLAS Life Sciences Group, Inc. | $2.77B | Mid cap | +615.10% | Nov 11, 2026 |
| NRIX | Nurix Therapeutics, Inc. | $2.77B | Mid cap | +179.69% | Oct 8, 2026 |
| NUVB | Nuvation Bio Inc. | $2.44B | Mid cap | +135.93% | Nov 2, 2026 |
| NBTX | Nanobiotix S.A. | $2.26B | Mid cap | +394.99% | Sep 29, 2026 |
| URGN | UroGen Pharma Ltd. | $2.25B | Mid cap | +135.11% | Nov 5, 2026 |
| NVCR | NovoCure Limited | $2.08B | Mid cap | +50.21% | Oct 29, 2026 |
| NANO.PA | Nanobiotix S.A. | $2.05B | Mid cap | +358.21% | Sep 29, 2026 |
| OSE.PA | OSE Immunotherapeutics SA | $88.75M | Micro cap | −47.94% | Sep 28, 2026 |
| VRCA | Verrica Pharmaceuticals Inc. | $84.35M | Micro cap | −13.25% | Nov 13, 2026 |
| OSTX | OS Therapies Incorporated | $76.68M | Micro cap | −34.00% | Nov 16, 2026 |
| CRDF | Cardiff Oncology, Inc. | $76.56M | Micro cap | −54.65% | Nov 12, 2026 |
| PLRX | Pliant Therapeutics, Inc. | $73.69M | Micro cap | −31.36% | Nov 5, 2026 |
| PMVP | PMV Pharmaceuticals, Inc. | $70.03M | Micro cap | −7.75% | Nov 16, 2026 |
| HRTX | Heron Therapeutics, Inc. | $59.27M | Micro cap | −77.04% | Nov 3, 2026 |
| IMMP | Immutep Limited | $56.00M | Micro cap | −77.11% | Sep 2, 2026 |
| 0RAD.L | OSE Immunotherapeutics SA | $51.87M | Micro cap | −48.50% | Sep 28, 2026 |
| CANTA.ST | Cantargia AB (publ) | $51.16M | Micro cap | −27.38% | Nov 25, 2026 |
| MDNA.TO | Medicenna Therapeutics Corp. | $31.26M | Micro cap | −56.48% | Nov 12, 2026 |
| 4582.T | SymBio Pharmaceuticals Limited | $31.19M | Micro cap | −57.43% | Oct 29, 2026 |
| BYSI | BeyondSpring Inc. | $28.37M | Micro cap | −62.09% | Nov 12, 2026 |
| LTRN | Lantern Pharma Inc. | $27.87M | Micro cap | −46.17% | Nov 11, 2026 |
| CLRB | Cellectar Biosciences, Inc. | $24.01M | Micro cap | −47.30% | Nov 12, 2026 |
| TPST | Tempest Therapeutics, Inc. | $17.86M | Micro cap | −89.96% | Nov 5, 2026 |
| LSTA | Lisata Therapeutics, Inc. | $15.68M | Micro cap | −30.40% | Nov 5, 2026 |
| BLRX | BioLineRx Ltd. | $11.79M | Micro cap | −26.63% | Aug 31, 2026 |
| LNAI | Lunai Bioworks Inc. | $9.97M | Micro cap | −89.34% | Sep 28, 2026 |
| 0GP7.L | Medivir AB (publ) | $5.78M | Micro cap | +1.60% | Nov 5, 2026 |
| BCAB | BioAtla, Inc. | $5.20M | Micro cap | −86.04% | Nov 12, 2026 |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.